|
2. Etiologie
|
|
|
Science Surgery: ‘Why do never-smokers get lung cancer?’ [Cancer Research UK]
|
|
|
|
|
|
“Smokers
can develop all types of lung cancers, although the association is
stronger for small cell lung cancer and squamous cell carcinoma, whereas
never-smokers are more likely to develop a non small cell lung cancer
called lung adenocarcinoma,” says Jamal-Hanjani. There are also
differences when you look at the DNA inside the tumour cells.
Non-smokers who develop lung cancer are more likely to have cells with a
fault in a gene called EGFR.
|
|
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
Standard chemo still most effective for throat cancers caused by HPV [Cancer Research UK]
|
|
|
|
|
|
The
study, published in The Lancet, found that patients taking either the
standard chemotherapy drug cisplatin or another targeted cancer drug
called cetuximab (Erbitux) experienced little difference in side
effects. But survival was significantly better in those who received the
standard of care drug cisplatin. Their cancers were also less likely to
return.
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
New dual-action cancer-killing virus [MRC]
|
|
|
|
|
|
“We
hijacked the virus’s machinery so the T-cell engager would be made only
in infected cancer cells and nowhere else in the body. The T-cell
engager molecule is so powerful that it can activate immune cells inside
the tumour, which are being supressed by the cancer, to attack the
fibroblasts.”
|
|
|
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
MYSTIC deals another blow to AstraZeneca as Imfinzi misses on OS [BiopharmaDive]
|
|
|
|
|
|
In
MYSTIC, NSCLC patients with 25% or greater PD-L1 expression were given
either Imfinzi, Imfinzi plus a CTLA-4 inhibitor called tremelimumab, or
standard of care chemotherapy. Results published last summer showed the
combination failed to significantly improve progression free survival,
dampening hopes that it would succeed on the tougher co-primary endpoint
of OS. Indeed, the pairing missed on that measure.
|
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
Innovative skin cancer drug available on Cancer Drugs Fund [NICE]
|
|
|
|
|
|
Patients
with a type of advanced skin cancer have a new treatment option as
pembrolizumab, also known as Keytruda, has been recommended for use on
the Cancer Drugs Fund. This recommendation applies to adults who have
melanoma that has spread to the lymph nodes, an important part of the
body’s natural defence system.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
EMA Recommends Granting a Marketing Authorisation for Apalutamide [ESMO]
|
|
|
|
|
|
On
15 November 2018, the European Medicines Agency’s (EMA’s) Committee for
Medicinal Products for Human Use (CHMP) adopted a positive opinion,
recommending the granting of a marketing authorisation for the medicinal
product apalutamide (Erleada), intended for the treatment of
non-metastatic castration resistant prostate cancer.
|
|
|
|
|
|
|
5.9.4 ENA
|
|
|
|
6.11 Patients
|
|
|
Tackling Cancer Anxiety [NY Times]
|
|
|
|
|
|
No
matter how long I deal with ovarian cancer, scanxiety threatens to
assert its nasty vigor in advance of periodic blood tests and abdominal
CTs.
|
|
|
|
|
|